BioNTech’s Seoul Test: A Pause in the Rally That Rode a Rival’s Coattails

The arithmetic of BioNTech’s recent surge was always going to demand a reckoning. A 20 percent single-day spike triggered by a competitor’s clinical win, followed by a 19 percent climb on the back of a leadership shake-up and regulatory approvals — that kind of momentum rarely consolidates without a breather. On Thursday, the stock delivered […] The post BioNTech’s Seoul Test: A Pause in the Rally…